Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain

Table 2 Treatment unit costs in 2009 [48, 49]

Intervention	Route of administration	Cost (€)	Presentation	Strength (mg)
TNF inhibitor
CZP	SC inj	474	Pre-filled syringe	200
IFX	IV inf	536.28	Vial	100
ADA	SC inj	514.15	Pre-filled syringe	40
ETA	SC inj	118.40	Pre-filled syringe	25
Conventional DMARDs
MTX	Oral	2.11	50 tablets	3
Azathioprine	Oral	5.78	50 tablets	50
Cyclosporine	Oral	65.90	30 tablets	100
Auranofin/gold sodium thiomalate	IM inj	6.73	1 vial	50
Hydroxychloroquine	Oral	7.33	30 tablets	200
Leflunomide	Oral	57.59	30 tablets	20
Penicillamine	Oral	6.75	30 tablets	250
Sulfasalazine	Oral	2.38	50 tablets	500
Palliative care	–	0	–	–
Methylprednisolone	IV inf	1.59	1 vial	40

ADA adalimumab, CZP certolizumab pegol, ETA etanercept, IFX infliximab, IM intramuscular, INF infusion, INJ injection, IV intravenous, MTX methotrexate, SC subcutaneous

ISSN: 1478-7547